Skip to main content

glucagon

Generic: GLUCAGON·Brand: BAQSIMI, GLUCAGEN, GLUCAGON, GVOKE HYPOPEN, GVOKE KIT, GVOKE PFS, GVOKE VIALDX, Gvoke

glucagon: developed by 1 company · 1 clinical trial tracked.

glucagon evidence translation

What we can confirm

What it means

Source-backed records connect glucagon to XERS; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could glucagon → XERS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors

Related indications

Treatment of severe hypoglycemia; indicated for use in pediatric and adult patients with diabetes age two years and aboveDiabetes Mellitus, Type 1
Development Pipeline (1)
CompanyPhase
Xeris Biopharma Holdings, Inc. (XERS)
Treatment of severe hypoglycemia; indicated for use in pedia…
Approved
Clinical Trials (1)

A Phase 3, Randomised, Open-label, Cross-over Study to Confirm the Clinical Efficacy and Safety of Dasiglucagon Versus Glucagon for the Treatment of Severe Hypoglycaemia in Asian Adults With Type 1 Diabetes (T1D) Including an Investigation of Dasiglucagon in a Japanese Adolescent Cohort

NCT06588504·Phase 1·NVO
Completed

Primary endpoint: Adults cohort: Time to plasma glucose (PG) recovery, where PG recovery is defined as the first increase in PG of greater than or equal to (>=) 20 milligrams per decilitre (mg/dL) (1.1 millimoles per litre [mmol/L]) from baseline

InterventionalRandomizedopen38 enrolledStarted 2024-09Completion 2025-071 site · JapanNovo Nordisk A/S

Frequently asked questions

Who is developing glucagon?

glucagon is being developed by Xeris Biopharma Holdings, Inc..

How many clinical trials involve glucagon?

BioSniper tracks 1 clinical trial involving glucagon.